FGWP
ABBV icon

Founders Grove Wealth Partners’s AbbVie ABBV Stock Holding History

Founders Grove Wealth Partners’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$740K Buy
2,939
+160
+6% +$34.4K 0.15% 93
2026
Q1 		$604K Buy
2,779
+125
+5% +$27.7K 0.14% 91
2025
Q4 		$606K Buy
2,654
+181
+7% +$41.2K 0.14% 92
2025
Q3 		$573K Buy
2,473
+86
+4% +$17.5K 0.13% 94
2025
Q2 		$443K Buy
2,387
+7
+0.3% +$1.3K 0.11% 96
2025
Q1 		$499K Hold
2,380
– – 0.14% 90
2024
Q4 		$423K Buy
+2,380
New +$438K 0.12% 91

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Founders Grove Wealth Partners's ABBV Position: Q2 2026 in Review

Founders Grove Wealth Partners increased its AbbVie (ABBV) stake by 5.8% in Q2 2026, buying an estimated $34.4K and bringing the position to 2,939 shares worth $740K. The position accounts for 0.15% of the portfolio, ranked #93.

Founders Grove Wealth Partners first reported a position in ABBV in Q4 2024 and has held it in 7 quarters since. 4,215 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Founders Grove Wealth Partners held 2,939 shares of AbbVie worth $740K as of Q2 2026.
  • Founders Grove Wealth Partners bought 160 AbbVie shares in Q2 2026, an estimated $34.4K.
  • AbbVie made up 0.15% of Founders Grove Wealth Partners's portfolio in Q2 2026, its #93 holding.
  • Founders Grove Wealth Partners first reported a position in AbbVie in Q4 2024 and has held it in 7 quarters since.
  • 4,215 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Founders Grove Wealth Partners's 13F filing for Q2 2026, filed 22 Jul 2026.